Back to search
FDAFDA · Food and drugs·Recall number D-0594-2024

Lidocaine HCL Injection, USP 2% 200mg/10mL (20mg/mL) and EPINEPHRINE HCl 1:200,000, 10 ml Single Dose Vial, Rx only, Compounded drug by Medivant Healthcare, 158 S Kyrene Rd, Chandler, AZ 85226, NDC 81483-0038-0, UPC 3 81483 00380 2

Published July 17, 2024 · Recall initiated: July 3, 2024

Summary

FDA records drug Class II recall D-0594-2024, published July 17, 2024 and initiated July 3, 2024. Recalling firm: TAILSTORM HEALTH INC; Status: Ongoing; Reported quantity: 12,525 10 mL vials; Lot: Lot Number: 2311003, Expiration Date: 11/13/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: reduced efficacy for epinephrine

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
TAILSTORM HEALTH INC
Distributor
Nationwide in the USA
Lot
Lot Number: 2311003, Expiration Date: 11/13/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lidocaine HCL Injection, USP 2% 200mg/10mL (20mg/mL) and EPINEPHRINE HCl 1:200,000, 10 ml Single Dose Vial, Rx only, Compounded drug by Medivant Healthcare, 158 S Kyrene Rd, Chandler, AZ 85226, NDC 81483-0038-0, UPC 3 81483 00380 2 recalled?

Yes. FDA published recall D-0594-2024 on July 17, 2024. Reported hazard: Subpotent Drug: reduced efficacy for epinephrine

What should I do if I have this product?

Voluntary: Firm initiated · Letter